Webinar | Women’s Nutrition: Nourishing Womanhood From Pregnancy To Menopause
11 September | 12 PM ET: Register Now

Instagram X-twitter Linkedin-in Youtube
GET IN TOUCH

Motif Neurotech

Motif Neurotech is a medical equipment manufacturing company that develops minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses
2022
Nov-50
11-50
Texas, United States

www.motifneuro.tech

Bioanalytical DevicesDrug Delivery and DevicesPersonalized Medicine Technologies
  • Bioanalytical Devices
  • Drug Delivery and Devices
  • Personalized Medicine Technologies
Innovation
Investment Funding
People
About
Products
Future Plan
M&A and Collabs
News

Innovation

Industry Problem

A substantial share of people with depression do not respond adequately to medication and existing implant procedures are invasive.

R&D Focus

Miniature wireless brain-computer interfaces and neuromodulation for treatment-resistant depression.

Innovative Solution

DOT is a small implanted stimulator designed for outpatient placement and home-based activation of brain networks linked with depression relief.

Investment Funding

Last Funding Stage

Series A

Total Funding Amount

$18.9M

Last Funding Amount

18.75M

Last Funding Date

1/24/2024

Startup Stage

Early Stage

Lead Investors

Arboretum Ventures, Dolby Family Ventures, Focalpoint Partners, Interface Capital, KdT Ventures

People

Founders

  • Jacob Robinson Ph.D
  • Sunil Sheth MD
  • Kaiyuan Yang
  • Sameer Sheth Ph.D

CEO

  • Jacob Robinson

About

Motif Neurotech is a medical equipment manufacturing company that develops minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses

Products

Product

DOT minimally invasive therapeutic brain-computer interface.

Star Product

DOT, because it is the lead therapeutic implant and the subject of the FDA-authorized trial.

Demo Product or Complete Product?

Clinical-stage device. The FDA authorized the first clinical trial in April 2026.

Future Plan

Market Expansion

Initial clinical development is focused on the United States, with broader mental-health applications planned.

Investment Funding

$18.75 million Series A announced in 2024; the company also reported £5.8 million in UK government grants in 2025.

M&A and Collabs

Collab

MintNeuro: strategic partnership on miniaturized implantable neurotechnology.

Collab

Rice University researchers: foundational technology and translational development.

Something missing or incorrect on this page? Help us enrich this information

Claim Now and Contribute